iOrganBio has appointed Karol Jarzabek as chief operating officer to lead and scale the company’s operations, manufacturing and supply chain functions. The appointment supports the company’s expansion of CellForge™, its AI-powered platform for precise human cell production, which is designed to support disease modeling, drug development and cell therapy workflows.

iOrganBio, recently emerged from stealth, focuses on intelligent cell manufacturing and New Approach Methodologies (NAMs) in line with FDA guidance. CellForge integrates data, automation and experimental control to enable predictable, reproducible and scalable human cell production for research and therapeutic applications.

Daniel Delubac, co-founder and CEO of iOrganBio, said: “We are advancing our infrastructure to enable predictable, reproducible and scalable manufacturing of human cells. Karol brings extensive experience designing operational structures and aligning teams across life science businesses, with a proven track record of translating strategy into measurable results. His leadership has helped elevate a private pharmaceutical company from approximately $30 million to more than $500 million in net revenue and transform an established brands division from a negative EBITDA contributor into a profitable business generating $800 million in gross revenue. This expertise will be essential as we support more partners and expand the impact of CellForge.”

Jarzabek brings broad experience in operational management and business transformation, including predictive analytics and deployment of AI-enabled systems across global organizations. He most recently served as vice president of portfolio operations at QHP Capital, leading value creation initiatives across 13 life science and pharmaceutical services companies. Previously, he held senior leadership roles at Azurity Pharmaceuticals, including vice president of strategic finance and president of established brands, where he oversaw M&A execution, operational integration and portfolio management.

“What impressed me about iOrganBio is how intentionally the platform was designed from the start. There is strong integration between the science and data infrastructure,” Jarzabek said. “The team is applying true engineering rigor to complex biological systems, creating a foundation that can actually scale. This approach has the potential to fundamentally change how therapies are developed for patients, and I am excited to help translate that vision into durable, scalable operations as the company grows.”

As COO, Jarzabek will coordinate cross-functional teams across all areas of the business and oversee operational execution, manufacturing scale-up and regulatory alignment. His appointment is expected to accelerate iOrganBio’s ability to expand its platform for partners and increase the reproducibility and reliability of human cell production at scale.

The leadership addition reflects the growing focus on operational excellence and infrastructure in cell and gene therapy, particularly in scaling AI-enabled and integrated manufacturing platforms. iOrganBio positions its CellForge platform as a foundation for more consistent and predictable human cell production to support translational research and therapeutic development.